Search results for: Value-Based Pricing
Filter search results
New: 50 Years of OHE Publications Are Available Online
2 April 2012
…was adopted, setting the tone for pricing for the next fifty years. In 1962, the Committee on the Safety of Drugs (CSD) was formed in the wake of the thalidomide…
Register Now for the OHE Conference on Drug Development in 2022
2 July 2012
…Medicines Agency Dr Jens Grueger, Head, Global Health Economics and Pricing, Roche Pharmaceuticals Dr Hannah Kettler, Senior Program Officer and Economist, The Bill & Melinda Gates Foundation Professor Fabio Pammolli,…
OHE Conference on Drug Development in 2022: Update
18 July 2012
…The Wharton School, University of Pennsylvania Dr Hans-Georg Eichler, Senior Medical Officer, European Medicines Agency Dr Jens Grueger, Head, Global Health Economics and Pricing, Roche Pharmaceuticals Dr Hannah Kettler, Senior…
Register Now for the OHE Conference on Drug Development in 2022
14 August 2012
…of UK and EU regulatory agencies, the pharmaceutical industry and payers — as well as leading experts in health technology assessment, pricing and reimbursement, and R&D structure and incentives. Among…
OHE has an Opening for an Economist
4 September 2012
…sector; familiarity with HTA and medicines pricing and reimbursement in practice in one or more countries; strong quantitative skills Applications must be received by Monday, 24 September 2012. Interviews for…
OHE Conference on the Future of Drug Development – Register Now
5 September 2012
…of UK and EU regulatory agencies, the pharmaceutical industry and payers — as well as leading experts in health technology assessment, pricing and reimbursement, and R&D structure and incentives. Among…
Valuing Co-Dependent Medical Technologies: Improving Methods and Processes
23 April 2013
…information, please contact Martina Garau. See also: Garau, M., Towse, A., Garrison, L., Housman, L. and Ossa, D. (2012) Can and should value based pricing be applied to molecular diagnostics?…
OHE Models Incentives for Antibiotic Drug Development
18 March 2014
The OHE model takes into account the value to society of new antibiotics as well as the risks and rewards for payers and the entities developing the new drugs. A…
How Will Demands for Effectiveness Evidence Change Drug Development?
23 April 2014
…R&D, outcomes research, medical affairs, and pricing and reimbursement. The intent was to capture information about the effect of CER/RE requirements on the drug development process now and in the…